Press announcements and conferences


If you want, you can send details about your upcoming scientific event by filling out the form on our Scientific events web site

New Chairman of the Main Board of ARPharM was Elected

08/07/2022, Sofia

At a regular meeting of the General Assembly of the Association of the Research-based Pharmaceutical Manufacturers in Bulgaria (ARPharM), held on May 19, 2022, two new members of the Association's Management Board (MB) were elected.

Dr. Stamen Bankovski, director for Bulgaria, Romania, and Hungary of the pharmaceutical company Astellas, was elected Chairman of the ARPharM Main Board.

The other new member of the Main Board is Dr. Boryana Alexieva - Head of Relations with Governmental Structures, Institutions and Patient Organizations in Janssen - the pharmaceutical companies of Johnson & Johnson, Bulgaria.

The new figures in the management of ARPharM will continue the organisation's efforts in the direction of improving Bulgarian patients' access to quality, modern and effective medical treatment and will cooperate with all state institutions and patient organisations for the preparation of balanced policies to improve the healthcare system in our country.

read more
A New Main Board of The Association Of Research-Based Pharmaceutical Manufacturers in Bulgaria Is Elected

May 31, 2021, Sofia

Dr. Svetoslav Tsenov is the New Chairperson of the Managing Board of ARPharM

The regular annual General Assembly of the Association of Research-based Pharmaceutical Manufacturers in Bulgaria (ARPharM), held on the 18th of May 2021 elected a new Managing Board of the Association.

Dr. Svetoslav Tsenov, Director and Head of Strategic Development for Bulgaria, Central and Eastern Europe, Greece, Portugal and the Baltic Region of the pharmaceutical company Astellas was elected Chairman of the Management Board of ARPharM for a two-years term. Dr. Krassimira Chemishanska, Executive Director of Amgen Bulgaria and Chairperson of the Association in the previous term, following a tradition of continuity, was elected a Vice-chairperson of the association.

read more
Interaction between pharmaceutical companies and medical professionals in COVID situation

May 12, 2020, Sofia

The Association of the Research-based Pharmaceutical Manufacturers (ARPharM) and its member companies are committed to the global fight against the COVID-19 pandemic due to coronavirus. Our thoughts are with the people affected by the infection and their loved ones, as well as with the doctors and pharmacists who are at the forefront in the fight to overcome the pandemic.

The Research-based pharmaceutical industry is focused on three key areas: • the development of new vaccines, diagnostics and drug therapies to combat COVID-19 - around 7 vaccine applicants and over 30 antiviral drugs at various stages of development or use are currently being investigated by innovative pharmaceutical companies in over 25 clinical trials to determine whether they are effective in preventing or treating patients with COVID-19 -;

read more
Coronavirus – your questions answered

Q. What is a coronavirus? Coronaviruses are a large family of viruses which may cause illness in animals or humans. In humans, several coronaviruses are known to cause respiratory infections ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The most recently discovered coronavirus causes coronavirus disease COVID-19.

COVID-19 is the infectious disease caused by the most recently discovered coronavirus. This new virus and disease were unknown before the outbreak began in Wuhan, China, in December 2019.

read more
What’s next?

12/05/2019 Diseases will not give up or disappear. Luckily, neither will science nor researchers. Just as they didn’t in the 1980s when the needle and the syringe were the only known way of injecting insulin, or in the 1990s when HIV meant a death penalty, or in the 2000s when destroying the cancer cells also affected the healthy cells.

What would it mean to slow down the beginning of Alzheimer’s disease? Could antibodies slow down our resistance to antibiotics and help overcome bacterial infections? What cell therapies would it take to avoid having aggressive chemotherapy ever again? And is there potential for gene therapy to reduce the toll of lifelong treatment?

read more

Members of the Association